Oler A, Whooley M A, Oler J, Grady D
Department of Medicine, University of California, San Francisco, School of Medicine, USA.
JAMA. 1996 Sep 11;276(10):811-5.
To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone.
Studies were retrieved using MEDLINE, bibliographies, and consultation with experts.
Only published trials that enrolled patients with unstable angina, randomized participants to aspirin plus heparin vs aspirin alone, and reported incidence of myocardial infarction or death were included in the meta-analysis.
Patient outcomes including MI or death, recurrent ischemic pain, and major bleeding during randomized treatment; revascularization procedures after randomization; and MI or death during the 2 to 12 weeks following randomization were extracted by 2 authors, 1 of whom was blinded to the journal, institution, and author of each study.
Six randomized trials were included. The overall summary relative risk (RR) of MI or death during randomized treatment was 0.67 (95% confidence interval [CI], 0.44-1.02) in patients with unstable angina treated with aspirin plus heparin compared with those treated with aspirin alone. The summary RRs for secondary endpoints in patients treated with aspirin plus heparin compared with those treated with aspirin alone were 0.68 (95% CI, 0.40-1.17) for recurrent ischemic pain; 0.82 (95% CI, 0.56-1.20) for MI or death 2 to 12 weeks following randomization; 1.03 (95% CI, 0.74-1.43) for revascularization; and 1.99 (95% CI, 0.52-7.65) for major bleeding. We found no statistically significant heterogeneity among individual study findings.
Our findings are consistent with a 33% reduction in risk of MI or death in patients with unstable angina treated with aspirin plus heparin compared with those treated with aspirin alone. The bulk of evidence suggests that most patients with unstable angina should be treated with both heparin and aspirin.
评估与单独使用阿司匹林治疗的不稳定型心绞痛患者相比,接受阿司匹林加肝素治疗的患者发生心肌梗死(MI)和死亡的风险。
通过MEDLINE、参考文献检索以及与专家咨询获取研究资料。
荟萃分析仅纳入已发表的试验,这些试验纳入了不稳定型心绞痛患者,将参与者随机分为阿司匹林加肝素组和单独使用阿司匹林组,并报告了心肌梗死或死亡的发生率。
由两名作者提取患者结局,包括随机治疗期间的心肌梗死或死亡、复发性缺血性疼痛和大出血;随机分组后的血运重建程序;以及随机分组后2至12周内的心肌梗死或死亡。其中一名作者对每项研究的期刊、机构和作者不知情。
纳入六项随机试验。与单独使用阿司匹林治疗的不稳定型心绞痛患者相比,接受阿司匹林加肝素治疗的患者在随机治疗期间发生心肌梗死或死亡的总体汇总相对风险(RR)为(0.67)((95%)置信区间[CI],(0.44 - 1.02))。与单独使用阿司匹林治疗的患者相比,接受阿司匹林加肝素治疗的患者次要终点的汇总RR分别为:复发性缺血性疼痛为(0.68)((95%)CI,(0.40 - 1.17));随机分组后2至12周内发生心肌梗死或死亡为(0.82)((95%)CI,(0.56 - 1.20));血运重建为(1.03)((95%)CI,(0.74 - 1.43));大出血为(1.99)((95%)CI,(0.52 - 7.65))。我们发现各研究结果之间无统计学显著异质性。
我们的研究结果表明,与单独使用阿司匹林治疗的不稳定型心绞痛患者相比,接受阿司匹林加肝素治疗的患者发生心肌梗死或死亡的风险降低了(33%)。大量证据表明,大多数不稳定型心绞痛患者应同时接受肝素和阿司匹林治疗。